Insulin Pump Market Trends

Global Insulin Pumps Market Overview

The Insulin Pumps Market Size was prized at USD 4.73 Billion in 2023 and is projected to grow from USD 5.46 Billion in 2024 to USD 14.99 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13.45% during the forecast period (2024 - 2032). The rising prevalence of diabetes worldwide and rising health consciousness are the key market drivers enhancing market growth. Furthermore, factors like increased research and development for bettering the performance of insulin pumps and rising per capita healthcare spending have also contributed to market expansion.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

In June 2nd, 2022, Insulet Corporation, a global leader in wireless insulin pump technology and tubeless devices announced its documented plan of injecting around $200 million into the forthcoming manufacturing site it is planning to set up at Johor within the next five years.

Diabeloop, the world leader in therapeutic AI, and SOOIL Development Company, a superior diabetes therapy company, announced on 3 June 2022 at the American Diabetes Association Scientific Sessions that they have entered into an agreement for worldwide development. The collaboration is expected to lead to clinical trials and expansion of their cooperation while enabling their products to reach as many patients as possible through new innovative solutions.

Insulet Corporation stated that the Omnipod DASH Insulin Management System will be available in Israel, Switzerland, Austria, Germany, Belgium and France in the coming weeks as from September 2020. This product has been exposed in Denmark, Norway, Finland and Sweden already.

Medtronic has cleared its MiniMedTM 770G hybrid closed loop system with FDA approval in September 2020. It can be connected to smartphones or modified for use even by kids aged two years old thanks to SmartGuard technology, just like any other full-featured insulin administration systems developed by Medtronic.

Insulin Pump Market Trends

• Rising population of diabetic patients is driving the market growth

Market CAGR for insulin pumps is driven by the rising number of diabetic people. Approximately 90–95% of people with diabetes worldwide have type 2 diabetes. Additionally, there is a desire for innovative management strategies due to the rising rates of type 2 diabetes diagnosis and treatment. Demand for these pumps is also driven by the rising number of type 2 diabetic patients who are insulin-dependent and by the transition of patients from MDI to painless & alternative treatments. Intelligent technologies, including AI, have quickly impacted the healthcare IT sector and are currently making steady progress in the management of diabetes. There is a demand for technologically sophisticated pumps due to the type 2 diabetes population's growing use of these pumps. For instance, according to Medtechdive, the global adoption rate of type 2 insulin pumps is about 5%, with an expected 15% growth by 2027.

Figure 1: Estimated number of people suffering from diabetics in 2021, 2030, and 2045 in million

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Both in industrialized and emerging nations, diabetes is becoming more common. The prevalence of diabetes is increasing, and some contributing factors are obesity and a sedentary lifestyle. The IDF Diabetes Atlas predicts that 537 million persons between the ages of 20 and 79 will have diabetes by 2021. Furthermore, it is predicted that there will be 643 million cases of diabetes worldwide by 2030 and 783 million cases by 2045. Additionally, the number of persons with type 1 diabetes is increasing worldwide, creating a sizable patient population that needs insulin to control their condition. Thus, driving the insulin pumps market revenue.

Insulin Pumps Market Segment Insights

Insulin Pumps Type Insights

The global insulin pump market segmentation, based on type, includes smart insulin pumps, traditional insulin pumps, and disposable insulin pumps. In 2022, the smart insulin pump segment dominated the market. The quick uptake of smart insulin devices among diabetic patients and technological improvements are the main market drivers. The demand for technologically advanced items is driven by the high demand for patient-friendly product control technologies is anticipated to drive market expansion.

March 2021 Roche has announced the release of the Accu-Chek Instant system, a new "connected" blood glucose monitoring (BGM) device that supports and enables Roche's integrated Personalised Diabetes Management (iPDM) strategy.  Accu-Chek Instant has Bluetooth links to the mySugr app, allowing for wireless uploading of blood glucose results.

Additionally, in 2022, disposable insulin pumps witnessed the fastest growth rate. Due to the growing senior citizen population and the prevalence of diseases like diabetes around the world, the market is anticipated to grow. The convenience of utilizing disposable insulin pumps also contributes to the market's expansion.

Insulin Pumps Accessories Insights

The Insulin Pumps Market segmentation, based on accessories, includes insulin reservoirs, infusion sets and infusion set insertion devices. The infusion set insertion devices segment dominated the market, accounting for 48.4% of market revenue (2.00 Billion). This category has the highest market share because insulin pumps often have their infusion sets changed every two to three days and because infusion sets are expensive. Over the forecast period, the market for insulin reservoirs or cartridges is anticipated to expand at a significant CAGR. Usually, an insulin cartridge must be inserted into the reservoir, or an insulin vial must be drawn into the reservoir.

Figure 1: Insulin Pumps Market, by Accessories, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Insulin Pumps Application Insights

The global insulin pump market segmentation, based on application, includes type I diabetes and type II diabetes. Due to the rise in type 1 diabetes prevalence worldwide, the type 1 diabetes segment commanded the market in 2022. For instance, the International Diabetes Federation (IDF) estimates that 1.2 million children and adolescents will develop type 1 diabetes worldwide in 2021. The proportion of the type 2 diabetes industry is predicted to rise significantly over the projected period due to the rising prevalence of Type 2 diabetes globally. Because of the expanding number of type 2 diabetics who are insulin-dependent and the patients migrating from MDIs to other treatment options like pumps, the market is anticipated to grow.

Insulin Pumps End-User Insights

The Market segmentation of Insulin Pumps, based on end-user, includes hospitals and clinics, home care, and laboratories. With a major revenue share in 2022, the hospitals and clinics segment led the market throughout the projected period. Due to the abundance of qualified healthcare workers, rising government financing, and rising private sector investment in the healthcare industry, the segment's significant share has been explained. The homecare segment will have the quickest CAGR during the projected period. Due to their simplicity, the sector's expansion is attributable to rising insulin pump usage knowledge and widespread use of these items at home.

Insulin Pumps Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The Asia-Pacific Insulin Pump Market area will dominate this market due to the adoption of lifestyle modifications, which has contributed to the increased prevalence of chronic conditions like diabetes and the expansion of this market. The growing geriatric population and increasing urbanization, which promote a sedentary lifestyle in the area, are additional factors contributing to the rising prevalence of type 2 diabetes worldwide. Moreover, China’s insulin pump market held the largest market share, and the Indian insulin pump market was the rapidly growing market in the Asia-Pacific region.

Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.

Figure 2: INSULIN PUMPS MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

North America insulin pump market accounts for the second-largest market share. Due to variables like the favorable reimbursement environment for these pumps in the U.S., the area was dominant. For instance, only 20% of the cost of a tubeless pump or a tubed pump is covered by Medicare Parts A & B, respectively. Moreover, U.S.A market of insulin pumps held the largest market share, and the Canadian market of insulin pump was the rapidly growing market in the Asia-Pacific region.

Europe’s insulin pump market is expected to grow at the fastest CAGR from 2024 to 2032. The increased incidence of diabetes will primarily fuel the market in Europe. World Health Organisation estimates that 60 million people in Europe have diabetes and that the disease causes over 3.4 million yearly fatalities throughout the continent. Further, the German market of insulin pump held the largest market share, and the UK market of insulin pumps was the rapidly growing market in the European region.

Insulin Pumps Key Market Players & Competitive Insights

Leading market players are largely investing in research and development to expand their product lines, which will help the market of insulin pumps, grow even more. The launch of new products, larger-scale mergers and acquisitions, contractual agreements, and collaboration with other organizations are significant market developments in which market participants engage to increase their global presence. The insulin pump industry must provide affordable products to develop and flourish in a more difficult and competitive business environment.

One of the major business strategies manufacturers use in the global insulin pump industry to increase the market sector and benefit customers are local manufacturing to lower operational costs. In recent years, the insulin pump industry has stipulated some of the most important medicinal benefits.  Major players in the insulin pump industry, including Abbott Laboratories, Braun Melsungen AG, Dickinson and Company, Hoffmann-La Roche AG, Insulet Corporation, and others, are funding operations for research and development to boost market demand.

Tandem Diabetes Care Inc is a medical device firm that creates insulin-dependent diabetes treatments. The company's main insulin pump products are three. The t: thin Insulin Delivery System is small enough to fit in a user's pocket. Customers with higher insulin requirements use the t: flex Insulin Delivery System. The t: thin G4 Insulin Delivery system features a touch screen and continuous glucose monitoring. In February 2022, Tandem Diabetes Care, Inc. received FDA approval for bolus insulin dosing on the t: slim X2 insulin pump via the t: connect mobile app. This is the first FDA-approved smartphone application to initiate insulin delivery on iOS and Android operating systems.

Medtronic plc is a medical device firm based in the United States. The operational and executive headquarters of the corporation are in Minneapolis, Minnesota, and the legal headquarters are in Ireland.  In Asia Pacific, Europe, the Americas, the Middle East, and Africa, it sells its products to third-party healthcare providers, clinics, hospitals, and institutions, including distributors, governmental healthcare programs, and group purchasing organizations. In April 2021, Medtronic introduced the Medtronic Extended infusion set in select European nations, the first and only infusion set that may be worn for up to 7 days. This development lengthens the period of time an infusion set may be worn, enabling users to continue using insulin pumps safely with fewer interruptions and insertions while also making their diabetes management routine more convenient and comfortable.

Key Companies in the market of insulin pump include

• Insulet Corporation


• Dickinson and Company


• Hoffmann-La Roche AG


• Abbott Laboratories


• Braun Melsungen AG


• Medtronic


• Becton


• Sanofi

Insulin Pumps Industry Developments

July 2023, Tandem Diabetes Care received the FDA approval for the world's smallest insulin pump called Tandem Mobi insulin pump.

April 2023, Medtronic received the FDA approval for the World's first meal detection technology enabled insulin pump called Medtronic MiniMed 780G System. The product is expected to significantly improve user experience and flexibility.

January 2023, Tandem Diabetes Care completed the acquisition of Switzerland based AMF Medical, an insulin pump maker. AMF is developing Sigi patch insulin pump which received FDA breakthrough device designation in 2022.

Insulin Pumps Market Segmentation

Insulin Pumps Type Outlook

• Smart Insulin Pumps


• Traditional Insulin Pumps


• Disposable Insulin Pumps

Insulin Pumps Accessories Outlook

• Insulin Reservoirs


• Infusion Sets


• Infusion Set Insertion Devices

Insulin Pumps Application Outlook

• Type I Diabetes


• Type II Diabetes

Insulin Pumps End-User Outlook

• Hospitals and Clinics


• Home Care


• Laboratories

Insulin Pumps Regional Outlook

• 
  

  North America

  
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  

  Europe

  
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  

  Asia-Pacific

  
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America